Pancreatic ductal adenocarcinoma is the fourth cause of death in the Western world.
Surgery remains the only treatment offering an advantage in terms of overall survival (5-year …

Pancreatic cancer has become the fourth leading cause of cancer death in the last two
decades. Only 3%-15% of patients diagnosed with pancreatic cancer had 5 year survival …

Background One of the major reasons for poor prognosis of pancreatic cancer is its high
resistance to currently available chemotherapeutic agents. In recent years, focal adhesion …

Gemcitabine has been a first-line chemotherapy agent for advanced pancreatic cancer,
which is associated with one of the lowest 5years survival rates among human cancers. Due …

Pancreatic ductal adenocarcinoma (PAC) stands as the poorest prognostic tumor of the
digestive tract with limited therapeutic options. PAC carcinogenesis is associated with the …

The occurrence and development of pancreatic cancer is a complex process convoluted by
multi-pathogenies, multi-stages and multi-factors. S100 proteins are members of the S100 …

In the past 15 years, we have seen few therapeutic advances for patients with pancreatic
cancer, which is the fourth leading cause of cancer-related death in the United States …

Degalactotigonin (1) and three other steroidal compounds solasodine (2), O‐acetyl
solasodine (3), and soladulcoside A (4) were isolated from the methanolic extract of …

Thienylhalomethylketones, whose chemical, biological, and pharmaceutical data are here
reported, are the first irreversible inhibitors of GSK-3β described to date. Their inhibitory …

BACKGROUND: The Id (inhibitor of DNA binding/differentiation) proteins belong to the helix-
loop-helix transcriptional regulatory factors, and play important roles in tumor development …